Related Experiment Video
Updated: Jul 16, 2026
Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat
Published on: June 4, 2012
High-dose vancomycin spacers provided early recovery without nephrotoxicity compared with standard-dose in
Ahmet Ersoy1, Ferhat Say1, Orhan Tokur2
1Department of Orthopaedics and Traumatology, Faculty of Medicine, Ondokuz Mayıs University, Türkiye.
Background:
Periprosthetic joint infections (PJIs) are commonly treated with two-stage revision surgery utilising antibiotic-loaded spacers; however, antibiotic release from spacers is limited and usually drops below effective levels a few days after placement. This study compared high-dose and standard-dose vancomycin-loaded spacers in terms of efficacy, safety, and overall treatment duration in a rat periprosthetic joint infection model.
Methods:
Thirty male Wistar albino rats (8-10 weeks old, 300-320 g) were housed individually at standard conditions. A periprosthetic infection model was established in the right knee of the rats using methicillin-resistant Staphylococcus aureus (MRSA) -contaminated Kirschner wires. Two weeks later, the infection was verified, and the Kirschner wires were removed. Rats were randomly divided into three groups (n = 10): standard-dose (SVanc) and high-dose (HVanc) vancomycin groups had 2.5 and 7.5% vancomycin in their spacers, respectively, while the control group had no spacers. All groups received intramuscular (IM) vancomycin and gentamicin for 4 weeks after spacer implantation. Microbiological counts and vancomycin levels in the blood and joint flush samples were measured, and histopathological assessments were conducted on the femur and kidneys.
Results:
After spacer implantation, MRSA was eliminated in the HVanc group with 4 weeks of treatment, while the SVanc group required 6 weeks of treatment (P < 0.001). Histopathological findings of the femoral medulla and cortical samples were better in the HVanc group compared with other groups (P = 0.007). Vancomycin levels in serum remained within safe limits in all groups, and kidney damage was not observed.
Conclusion:
The use of high-dose vancomycin spacers might accelerate the transition period, which in turn reduces the duration of systemic antibiotic use and mitigates the risk of nephrotoxicity. Thus, this method may decrease the medical costs associated with PJI treatment.
Insights
High-dose vancomycin spacers effectively treated periprosthetic joint infections (PJIs) in rats, reducing treatment time and systemic antibiotic use. This approach shows promise for safer and more cost-effective PJI management.
Area of Science:
- Orthopedic Surgery
- Infectious Diseases
- Pharmacology
Background:
- Periprosthetic joint infections (PJIs) are a significant complication of joint replacement surgery.
- Current treatments often involve two-stage revision surgery with antibiotic-loaded spacers, but antibiotic elution is limited.
- Existing spacers release antibiotics below effective levels within days, necessitating further treatment.
Purpose of the Study:
- To compare the efficacy and safety of high-dose versus standard-dose vancomycin-loaded spacers in a rat model of PJI.
- To evaluate the impact on treatment duration and systemic antibiotic exposure.
- To assess potential nephrotoxicity associated with different vancomycin doses.
Main Methods:
- A rat model of PJI was established using methicillin-resistant Staphylococcus aureus (MRSA).
- Rats were divided into three groups: control, standard-dose vancomycin spacer (SVanc), and high-dose vancomycin spacer (HVanc).
- All groups received systemic antibiotics; microbiological, pharmacokinetic, and histopathological assessments were performed.
Main Results:
- High-dose vancomycin (HVanc) spacers eradicated MRSA in 4 weeks, compared to 6 weeks for standard-dose (SVanc) spacers (P < 0.001).
- Histopathological analysis showed superior bone healing in the HVanc group.
- Serum vancomycin levels remained safe, and no kidney damage was observed.
Conclusions:
- High-dose vancomycin spacers accelerate the treatment of PJIs, reducing the need for prolonged systemic antibiotics.
- This method mitigates nephrotoxicity risks and may lower overall treatment costs.
- High-dose vancomycin spacers represent a promising advancement in PJI management.
Related Concept Videos
01:25Mechanism of Antibiotic Resistance in MRSA
01:25Clinical Significance of Antibiotic Resistance